ArticleLeukemia2015
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04612582 (A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）
Who cites it
24 citing papers in PubMed, 71 citations in OpenAlex.
- Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.Haematologica · 2021Trial
- Trial
- Trial
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.Blood cancer journal · 2018Trial
- Article
- Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Review
- Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.Cancer immunology research · 2022Article
- Identification of patients at high risk of secondary extramedullary multiple myeloma development.British journal of haematology · 2022Article
- The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.Frontiers in oncology · 2022Article
- Current and Novel Alkylators in Multiple Myeloma.Cancers · 2021Review
- Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres.Bone marrow transplantation · 2021Article
- Therapeutic Advances in Oncology.International journal of molecular sciences · 2021Review
- Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.Frontiers in oncology · 2021Article
- Frontline therapy for newly diagnosed patients with multiple myeloma.Blood research · 2020Review
- Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.Frontiers in oncology · 2020Review
- Article
- Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.Blood advances · 2019Article
- [Application of 8-color fluorescent antibody panels to detect minimal residual disease in multiple myeloma and its significance].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Highlights of Abstracts on Plasma Cell Dyscrasia in the Annual Conference ISHBT (Kochi).Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.